Literature DB >> 27190969

LongoVital- An Imminent Therapeutic Modality: An Unseen Drug Review with Advanced Features and Hypothesis.

Ruchika Khanna1, Nisha Dua2, Anand Kumar3, Ruchit Khanna4, Pyare Mohan Lal Khanna5.   

Abstract

Herbal medication still happens to be the backbone of the major world's population essentially because of the assumption that these drugs are free of any side effects and easily available. LongoVital (LV) is a herbal preparation with documented immune-modulatory and immune-stimulatory effects in man. Various studies conducted to date, have shown LV to have prolonged and beneficial impact in the treatment of orofacial diseases, when administered in recommended daily doses. With its combined antimicrobial and immunostimulatory effects, LV can be regarded as an emerging therapeutic modality in the treatment of orofacial diseases.

Entities:  

Keywords:  Herbal; Immune-modulatory; Immunostimulatory; Orofacial diseases

Year:  2016        PMID： 27190969      PMCID： PMC4866267          DOI： 10.7860/JCDR/2016/17605.7698

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN： 0973-709X


  13 in total

1.  LongoVital in the treatment of Sjögren's syndrome.

Authors:  A Pedersen; N Gerner; I Palmvang; M Høier-Madsen
Journal:  Clin Exp Rheumatol       Date:  1999 Sep-Oct       Impact factor: 4.473

2.  LongoVital and herpes labialis: a randomised, double-blind, placebo-controlled study.

Authors:  A Pedersen
Journal:  Oral Dis       Date:  2001-07       Impact factor: 3.511

3.  LongoVital in the prevention of recurrent aphthous ulceration.

Authors:  A Pedersen; H P Hougen; B Klausen; K Winther
Journal:  J Oral Pathol Med       Date:  1990-09       Impact factor: 4.253

Review 4.  The efficacy of herbal medicine--an overview.

Authors:  Edzard Ernst
Journal:  Fundam Clin Pharmacol       Date:  2005-08       Impact factor: 2.748

5.  Norwegian LongoVital and recurrent aphthous ulceration: a randomized, double-blind, placebo-controlled study.

Authors:  I Kolseth; B B Herlofson; A Pedersen
Journal:  Oral Dis       Date:  2005-11       Impact factor: 3.511

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

Review 8.  Herbal medicine: current status and the future.

Authors:  Sanjoy Kumar Pal; Yogeshwer Shukla
Journal:  Asian Pac J Cancer Prev       Date:  2003 Aug-Dec

Review 9.  Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy.

Authors:  Yuchen Fan; James J Moon
Journal:  Vaccines (Basel)       Date:  2015-08-27

10.  The BMP Pathway Participates in Human Naive CD4+ T Cell Activation and Homeostasis.

Authors:  Víctor G Martínez; Rosa Sacedón; Laura Hidalgo; Jaris Valencia; Lidia M Fernández-Sevilla; Carmen Hernández-López; Angeles Vicente; Alberto Varas
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.